アスコルビン酸 (Synonyms: Vitamin C; L-Ascorbic acid; Vitamin C; 50-81-7)

Name: L-Ascorbic acid
Brand: MedChemExpress
SKU: HY-B0166
Rating: 5.0 (80 reviews)

製品番号: HY-B0166 純度: 99.96%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Ca_v3.2 channels with an IC₅₀ of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 50-81-7

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 33	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 33	在庫あり	Estimated Time of Arrival: December 31
Solid
500 mg	$30	在庫あり	Estimated Time of Arrival: December 31
1 g	$50	在庫あり	Estimated Time of Arrival: December 31
5 g	$75	在庫あり	Estimated Time of Arrival: December 31
10 g	$90	在庫あり	Estimated Time of Arrival: December 31
25 g	$126	在庫あり	Estimated Time of Arrival: December 31
50 g	$152	在庫あり	Estimated Time of Arrival: December 31
> 100 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 80 publication(s) in Google Scholar

Other Forms of L-Ascorbic acid:

L-Ascorbic acid-¹³C₆ 在庫あり
L-Ascorbic acid-¹³C 在庫あり
L-Ascorbic acid-¹³C-1 在庫あり
L-Ascorbic acid-¹³C-2 在庫あり
L-Ascorbic acid-d₂ 在庫あり
L-Ascorbic acid-¹³C₆-1 在庫あり
L-Ascorbic acid sodium salt 在庫あり
L-Ascorbic acid (GMP Like) 在庫あり
L-Ascorbic acid (GMP) 在庫あり
L-Ascorbic acid (Standard) 在庫あり
Niacinamide ascorbate お問い合わせ
L-Ascorbic acid-¹³C-3 お問い合わせ
L-Ascorbic acid-¹³C-4 お問い合わせ
L-Ascorbic acid calcium dihydrate お問い合わせ

顧客検証

2D/3D Cell Culture and Differentiation

Cell Proliferation/Viability Assay

IHC

: L-Ascorbic acid purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Aug 15:313:122756. [Abstract]; (A) Representative images of Alizarin Red staining on 14 and 21 days of BMSCs seeded on porous tantalum scaffolds and cultured in osteogenic induction medium containing 1 M β-glycerophosphate (β-Glycerophosphate disodium salt pentahydrate) and 10 mM ascorbic acid ( L-Ascorbic acid). (B) Quantitative analysis of dissolved calcium nodules after 14 days and 21 days (n = 4).

: L-Ascorbic acid purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 May 27;13(6):653.; L-Ascorbic acid (Vitamin C) (50-500 μM; 6 h) significantly increases the viability of heat-stressed gastric cancer cells at concentrations of 200 μM and 300 μM.

: L-Ascorbic acid purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 May 31;24(1):192. [Abstract]; L-Ascorbic acid (AA) (150 μL of 1.5 M; i.p.; every two days) enhances the expression of GPX4 and SLC7A11 proteins in mouse liver.

: L-Ascorbic acid purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 May 31;24(1):192. [Abstract]; L-Ascorbic acid (AA) (150ul of 1.5 M; i.p.; every two days) significantly decreases the expression of Ki67 in C57BL/6 mice.

: L-Ascorbic acid purchased from MedChemExpress. Usage Cited in: Food Funct. 2022 May 10;13(9):5089-5101. [Abstract]; L-Ascorbic acid (Vitamin C) (100 μM; 10 min-4 h) upregulates the protein expression levels of IGF-1, p-IGF-1R, and SVCT2 in a time-dependent manner.

: L-Ascorbic acid purchased from MedChemExpress. Usage Cited in: Cell Biol Toxicol. 2023 Jun;39(3):679-702. [Abstract]; L-Ascorbic acid (300 μM, 10 μL intrathecal injection) reduces the levels of CaV3.2, p-CaMKII, and Cx43 in mice.

: L-Ascorbic acid purchased from MedChemExpress. Usage Cited in: Antioxid Redox Signal. 2020 Dec 10;33(17):1191-1208. [Abstract]; L-Ascorbic acid (Vitamin C) (250 μM, 1 h) significantly alleviates the growth suppression induced by combined SAS and PAG treatment only in OVISE cells, but shows no effect in KOC-7C cells.

Calcium Channel アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Human Endogenous Metabolite Microbial Metabolite

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Ca_v3.2 channels with an IC₅₀ of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor^[1]^[2]^[3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells^[4].

IC₅₀ & Target

T-type calcium channel

Microbial Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
CFPAC-1	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
Erythrocyte	EC₅₀	119.87 μg/mL Compound: Ascorbic acid	Antioxidant activity in erythrocytes assessed as inhibition of hemolysis Antioxidant activity in erythrocytes assessed as inhibition of hemolysis	[PMID: 22677320]
Erythrocyte	EC₅₀	96.625 μg/mL Compound: Ascorbic acid	Hemolysis of human erythrocytes after 30 mins by spectrophotometry Hemolysis of human erythrocytes after 30 mins by spectrophotometry	[PMID: 23811092]
HCT-116	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HEK293	EC₅₀	0.5 nM Compound: Ascorbic acid	Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay	[PMID: 19243956]
HEK293	EC₅₀	156 μM Compound: 54670067	Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810) Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810)	10.5281/zenodo.7360349
HeLa	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HepG2	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HFF	IC₅₀	>100 μM Compound: L-ASA	Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HL-60	IC₅₀	0.01 μM Compound: Vitamin C	Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method	[PMID: 19555121]
HL-60	IC₅₀	10.2 μM Compound: Vitamin C	Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay	[PMID: 16562834]
HL-60	IC₅₀	9.7 μM Compound: Vitamin C	Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay	[PMID: 12762791]
J774.A1	IC₅₀	>100 μM Compound: AA	Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis	[PMID: 33422907]
MCF7	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
RD	EC₅₀	>2270 μM Compound: AA	Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22390834]
SW-620	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]

体外実験

The anti-cancer effects of L-Ascorbic acid are determined by sodium-dependent vitamin C transporter 2 (SVCT-2), a transporter of L-ascorbic acid. L-Ascorbic acid (0.1 μM-2 mM) exhibits anti-cancer effects according to SVCT-2 expression and L-ascorbic acid uptake. Human colorectal cancer cell lines displays differential responses to L-ascorbic acid, primarily depending on the expression level of SVCT-2^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	High SVCT-2 expressing cell lines Sw620, Sw480, LoVo, SNU-C4; Low SVCT-2 expressing cell lines HCT15, HCT116, DLD-1, CoLo-205
Concentration:	0, 0.1 μM, 1 μM, 10 μM, 0.1 mM, 0.5 mM, 1 mM, and 2 mM
Incubation Time:	24 hours
Result:	Some high SVCT-2 expressing cancer cells demonstrated a dramatic cell-autonomous inhibitory effect of L-ascorbic acid. Low SVCT-2 expressing cell lines showed biphasic responses to L-ascorbic acid.

Western Blot Analysis^[4]

Cell Line:	Sw620, Sw480, LoVo, SNU-C4, HCT15, HCT116, DLD-1, CoLo-205 cell lines
Concentration:	1 mM
Incubation Time:
Result:	The cell lines showed different levels of SVCT-2 expression in western blot analyses: Sw620, Sw480, and Lovo expressed high levels of SVCT-2 whereas HCT116, HCT15, and DLD-1 expressed low levels.

体内実験

L-Ascorbic acid/Tolbutamide produces hypoglycaemic activity in a dose dependant manner in normal (60 mg/kg) and diabetic (40 mg/kg) condition. In the presence of L-ascorbic acid, Tolbuatmide (20 mg/kg) produces early onset of action and maintained for longer period compared to Tolbutamide matching control^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal rats:Albino rats of either sex weighing between 125-175 g^[5]
Dosage:	Group I received L-ascorbic acid 60 mg/kg, Group II received Tolbutamide 20 mg/kg and Group III was given L-ascorbic acid (60 mg/kg) prior to the administration of tolbutamide 20 mg/kg
Administration:	Administered orally
Result:	L-ascorbic acid at the dose of 60 mg/kg produced 50.91% blood glucose reduction at 0.5 h and 20 mg/kg body weight of Tolbutamide produced 33% at 4 h as peak effects. In the presence of L-ascorbic acid (60 mg/kg), the action of Tolbutamide was early in onset and maintained for 6 h.

Animal Model:	Diabetic rats:Albino rats of either sex weighing between 125 to 175 g were fasted overnight before injection with Alloxan^[5]
Dosage:	Group I received L-ascorbic acid 40 mg/kg and Group II received Tolbutamide 20 mg/kg while Group III was given L-ascorbic acid 40 mg/kg prior to Tolbutamide administration (20 mg/kg).
Administration:	Oral administration
Result:	L-ascorbic acid (40 mg/kg alone) produced 42.53% blood glucose reduction at 1.5 h and Tolbutamide 20 mg/kg produced 45.09 at 4 h. Administration of L-ascorbic acid 40 mg/kg body weight prior to Tolbutamide produced antidiabetic activity at 0.5 h and was maintained for 6 h.

分子量

176.12

分子式

C₆H₈O₆

CAS 番号

50-81-7

Appearance

Solid

Color

White to off-white

SMILES

OC([C@@]1([H])[C@H](CO)O)=C(O)C(O1)=O

Structure Classification

Others

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

RT, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (RT, protect from light)

溶剤 & 溶解度

体外:

H₂O : ≥ 100 mg/mL (567.79 mM)

DMSO : 100 mg/mL (567.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.6779 mL	28.3897 mL	56.7795 mL
5 mM	1.1356 mL	5.6779 mL	11.3559 mL
10 mM	0.5678 mL	2.8390 mL	5.6779 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (567.79 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

純度とドキュメンテーション

純度: 99.97%

Select Batch:

データシート (281 KB) SDS (394 KB)

COA (252 KB) RP-HPLC (205 KB) LCMS (92 KB) Elemental Analysis Report (111 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Sebastian J Padayatty, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003 Feb;22(1):18-35. [Content Brief]

[2]. Michael T Nelson, et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83. [Content Brief]

[3]. Aleksander Hinek, et al. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82. [Content Brief]

[4]. Sungrae Cho, et al. Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression. Sci Rep. 2018 Jul 27;8(1):11372. [Content Brief]

[5]. Satyanarayana Sreemantula, et al. Influence of antioxidant (L- ascorbic acid) on tolbutamide induced hypoglycaemia/antihyperglycaemia in normal and diabetic rats. BMC Endocr Disord. 2005 Mar 3;5(1):2. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	5.6779 mL	28.3897 mL	56.7795 mL	141.9487 mL
	5 mM	1.1356 mL	5.6779 mL	11.3559 mL	28.3897 mL
	10 mM	0.5678 mL	2.8390 mL	5.6779 mL	14.1949 mL
	15 mM	0.3785 mL	1.8926 mL	3.7853 mL	9.4632 mL
	20 mM	0.2839 mL	1.4195 mL	2.8390 mL	7.0974 mL
	25 mM	0.2271 mL	1.1356 mL	2.2712 mL	5.6779 mL
	30 mM	0.1893 mL	0.9463 mL	1.8926 mL	4.7316 mL
	40 mM	0.1419 mL	0.7097 mL	1.4195 mL	3.5487 mL
	50 mM	0.1136 mL	0.5678 mL	1.1356 mL	2.8390 mL
	60 mM	0.0946 mL	0.4732 mL	0.9463 mL	2.3658 mL
	80 mM	0.0710 mL	0.3549 mL	0.7097 mL	1.7744 mL
	100 mM	0.0568 mL	0.2839 mL	0.5678 mL	1.4195 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

L-Ascorbic acid Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

アスコルビン酸 (Synonyms: Vitamin C; L-Ascorbic acid; Vitamin C; 50-81-7)

カスタマーレビュー

Other Forms of L-Ascorbic acid:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Calcium Channel アイソフォーム固有の製品をすべて表示:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

L-Ascorbic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

アスコルビン酸 (Synonyms: Vitamin C; L-Ascorbic acid; Vitamin C; 50-81-7)

カスタマーレビュー

Other Forms of L-Ascorbic acid:

アスコルビン酸 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Calcium Channel アイソフォーム固有の製品をすべて表示:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

アスコルビン酸 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

L-Ascorbic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

アスコルビン酸関連抗体

アスコルビン酸関連抗体